Search results for "Continuation"

showing 10 items of 276 documents

Adalimumab vs Azathioprine in the Prevention of Postoperative Crohn's Disease Recurrence. A GETECCU Randomised Trial.

2017

Background and aims Postoperative recurrence of Crohn's disease [POR-CD] is almost certain if no prophylaxis is administered. Evidence for optimal treatment is lacking. Our aim was to compare the efficacy of adalimumab [ADA] and azathioprine [AZA] in this setting. Methods We performed a phase 3, 52-week, multicentre, randomised, superiority study [APPRECIA], in which patients with ileocolonic resection were randomised either to ADA 160-80-40 mg subcutaneously [SC] or AZA 2.5 mg/kg/day, both associated with metronidazole. The primary endpoint was endoscopic recurrence at 1 year [Rutgeerts i2b, i3, i4], as evaluated by a blinded central reader. Results We recruited 91 patients [median age 35.…

Crohn’s diseaseAdultMalemedicine.medical_specialtyAzathioprineGastroenterology03 medical and health sciences0302 clinical medicineCrohn DiseaseInternal medicineadalimumabAzathioprinemedicineClinical endpointAdalimumabSecondary PreventionHumansAdverse effectPostoperative CareCrohn's diseaseazathioprinebusiness.industryAdalimumabGastroenterologyGeneral Medicinemedicine.diseaseSurgeryDiscontinuationCrohn's diseaseMetronidazole030220 oncology & carcinogenesisUnselected population030211 gastroenterology & hepatologyFemalebusinessImmunosuppressive Agentsmedicine.drug
researchProduct

Déclaration et vérification des créances. Une créance inscrite au plan peut être admise pour un montant supérieur

1995

International audience; (Com. 14 juin 1994, Sté Interlac c/ M. Natali et autre)

CréancierAdmission des créances[SHS.DROIT]Humanities and Social Sciences/Law[SHS.DROIT] Humanities and Social Sciences/LawREDRESSEMENT ET LIQUIDATION JUDICIAIRESMontantPlan de continuation
researchProduct

Créancier de l'art. 4O. Droit de poursuite individuelle, Liquidation judiciaire, Référé-provision, Condamnation du liquidateur au paiement immédiat d…

1991

International audience

CréancierConsultation[SHS.DROIT]Humanities and Social Sciences/Law[SHS.DROIT] Humanities and Social Sciences/LawREDRESSEMENT ET LIQUIDATION JUDICIAIRESPlan de continuationDélai de paiementComputingMilieux_MISCELLANEOUS
researchProduct

Experimenting Through Neuromarketing to Measure the Impact of Spanish Cultural Heritage

2020

This is the continuation of a study based on the traditional image model of destination, formed by the constructions of cognition, emotion, and image. The objective is to study the model through a deconstruction in all forms through the application of neuroscience, a system of structural equations, virtual reality, and the Spanish architectural and cultural heritage as a stimulus. Variables were studied with an electroencephalogram through brain bioelectric wave responses, alpha and beta. The deconstruction of the image model consists of evaluating the hypotheses of the traditional image model of the destination in all its possible forms, giving rise to 3 models. Model 1. When cognition is …

Cultural heritageTourism marketingCognitive scienceContinuationNeuromarketingCognitionVirtual realityPsychology
researchProduct

Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepa…

2017

Summary Real-world studies are relevant to complement clinical trials on novel antiviral therapies against chronic hepatitis C; however, clinical practice data are currently limited. This study investigated effectiveness and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r)±dasabuvir (DSV)±ribavirin (RBV) for treatment of HCV genotype (GT) 1 and GT4 infection in a large real-world cohort. The German Hepatitis C Registry is an observational cohort study prospectively collecting clinical practice data on direct-acting antiviral therapies. Patients with GT1/4 infection treated with OBV/PTV/r±DSV±RBV were analysed. Effectiveness was assessed by sustained virologic response in 558 patients…

CyclopropanesLiver CirrhosisMaleHepacivirusSeverity of Illness IndexCohort Studieschemistry.chemical_compound0302 clinical medicine2-NaphthylamineGermanyMedicineAnilides030212 general & internal medicineSulfonamidesDasabuvirValineHepatitis CMiddle AgedViral LoadInfectious DiseasesTreatment Outcome030211 gastroenterology & hepatologyDrug Therapy CombinationFemalemedicine.drugAdultmedicine.medical_specialtyMacrocyclic CompoundsGenotypeProlineLactams Macrocyclic03 medical and health sciencesVirologyOmbitasvir/paritaprevir/ritonavirInternal medicineHumansUracilAgedRitonavirHepatologybusiness.industryHepatitis C Chronicmedicine.diseaseVirologyOmbitasvirDiscontinuationRegimenchemistryParitaprevirRitonavirCarbamatesbusinessJournal of viral hepatitis
researchProduct

Can the response to Omalizumab be influenced by treatment duration? A real-life study

2017

Objective It is unknown whether Omalizumab effectiveness changes over the course of time. Our retrospective real-life study tried to analyze whether Omalizumab response may be influenced by treatment duration. Methods 340 severe asthmatics treated with Omalizumab for different periods of time were recruited. They were subdivided into 4 groups according to the Omalizumab treatment length: 60 months. Omalizumab treatment results (FEV1, exacerbations, ACT, SABA use, asthma control levels, medications used e and ICS doses) were compared. Results ACT, exacerbations, GINA control levels, ICS doses and SABA use were similar in all groups with different Omalizumab treatment durations. Using a linea…

CyclopropanesMaleSevere asthmaTime FactorsTreatment durationQuinolineEffectivenessOmalizumabOmalizumabAcetatesAdrenal Cortex Hormone0302 clinical medicineAdrenal Cortex HormonesRetrospective StudieForced Expiratory VolumeMedicinePharmacology (medical)Anti-Asthmatic Agents030212 general & internal medicineLead (electronics)Adrenergic beta-AgonistConfoundingEffectiveneReal-lifeResponseAdrenergic beta-AgonistsMiddle AgedTreatment OutcomeEffectiveness; Omalizumab; Real-life; Response; Severe asthma; Treatment duration; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)QuinolinesLinear ModelFemaleHumanmedicine.drugAdultPulmonary and Respiratory Medicinemedicine.medical_specialtyTime FactorSulfidesSettore MED/10 - Malattie Dell'Apparato RespiratorioTreatment duration03 medical and health sciencesInternal medicineHumansAnti-Asthmatic AgentMontelukastRetrospective StudiesAsthmaAcetatebusiness.industryBiochemistry (medical)Retrospective cohort studymedicine.diseaseAsthmaDiscontinuationSurgery030228 respiratory systemLinear ModelsbusinessPulmonary Pharmacology & Therapeutics
researchProduct

QCD sum rule calculation ofK ℓ3 form factors

1992

We present a combined finite energy sum rule (FESR) and analytic continuation by duality (ACD) calculation of the (neutral)K l3 decay. We confirm the Callan-Treiman relation and investigate the validity of a linear fit for the form factors. Furthermore, we obtain ζ=−0.1...−0.3, consistent with the mean experimental value ζ=−0.1±0.09.

Discrete mathematicsQuantum chromodynamicsPhysics and Astronomy (miscellaneous)Analytic continuationSum rule in integrationForm factor (quantum field theory)Astrophysics::Cosmology and Extragalactic AstrophysicsLinearity of differentiationRule of sumSum rule in quantum mechanicsQuantum field theoryEngineering (miscellaneous)MathematicsMathematical physicsZeitschrift für Physik C Particles and Fields
researchProduct

Changing Trends in Drug Prescription and Causes of Treatment Discontinuation of First Biologic Over Ten Years in Psoriasis in the Spanish Biobadaderm…

2020

Background and objectives: Current psoriasis guidelines do not usually include recommendations about first line classical or biologic treatment. The objectives of this study were: to describe shifts in the prescription of the first biological treatment, and to compare treatment withdrawal and rates of adverse events over ten years. Material and methods: Biobadaderm registry was analyzed to describe: first biological prescription in bio-naive patients, adverse events rate and reasons for drug withdrawal comparing three periods of time (2008-2010, 2011-2014, 2015-2018). Results: Anti-TNF drugs were the most prescribed biological drug from 2008 to 2010. Ustekinumab has become the most prescrib…

Drugmedicine.medical_specialtyHistologyBiologicmedia_common.quotation_subjectDiscontinuationDermatologyBiologic treatmentPathology and Forensic Medicine030207 dermatology & venereal diseases03 medical and health sciencesDrug withdrawal0302 clinical medicinePsoriasisUstekinumabTrendmedicinePsoriasisMedical prescriptionIntensive care medicineAdverse effectmedia_commonbusiness.industryBiobadadermmedicine.diseaseDiscontinuationTreatment030220 oncology & carcinogenesisbusinessmedicine.drug
researchProduct

5PSQ-096 Hazard vulnerability analysis to evaluate the risk of drug shortages according to therapeutic class

2020

Background and importance Drug shortages are a critical challenge for the public health system, as highlighted by EAHP’s position paper. They have a negative impact on quality and efficiency of patient care. Aim and objectives The aim of our study was the application of a revised hazard vulnerability analysis (HVA) to assess which therapeutic classes of drugs are at greatest risk of shortages. Material and methods In September 2019, we analysed the drugs present in our hospital therapeutic formulary and checked which ones were included in the Italian Medicines Agency shortages list: 43 drugs were found. For each drug, we assigned a score using a revised HVA which consists of three macro are…

Drugmedicine.medical_specialtybusiness.industryPublic healthmedia_common.quotation_subjectLorazepamTazobactamDiscontinuationPneumococcal vaccineEnvironmental healthmedicineFormularybusinessDidanosinemedicine.drugmedia_commonSection 5: Patient Safety and Quality assurance
researchProduct

797 Infliximab in the Treatment of Pediatric Ibd: A Single Centre Experience

2010

Background and aims: The biological treatment of IBD acts on different stages of immunophysiopathological processes of the disease. We describe evolution and clinical response to Infliximab in paediatric patients affected by IBD diagnosed and followed at our centre. Methods: In the last triennial period at our Department of Paediatrics in Palermo 53 infusions of Infliximab were administrated to our patients affected by severe forms of IBD. All patients but one were affected by several forms of CD. Only one child was affected by U.C. associated to pyoderma gangrenosum. The total number of infusions were administrated according the ACCENT 1 study at a dose of 5 mg/Kg. All the infusions were p…

Drugmedicine.medical_specialtybusiness.industrymedia_common.quotation_subjectDiseasemedicine.diseaseInfliximabDiscontinuationSingle centreTolerabilityInternal medicinePediatrics Perinatology and Child HealthmedicinebusinessPyoderma gangrenosummedia_commonPaediatric patientsmedicine.drugPediatric Research
researchProduct